Notalgia Paresthetica (NP) Case Study

Click here for a PDF version of this case study

Study Characteristics

Study Phase: II
Patient Population: 126 patients with Notalgia Paresthetica (NP) (Pruritus associated with NP)
IP Route of Administration: Systemic (oral)
Site Distribution: 33 sites (USA and Canada)
Study Procedures: Photographs, Pharmacokinetics, Electrocardiograms

Study Challenges

Patient awareness: Challenge in advertisement as patients are often unaware of the name of their condition
Run-in period (screening): To ensure the enrollment of highly compliant patients and those with consistent itch
Patient compliance: Primary endpoints were relying on patient-reported assessments
Uncommon indication: PI with little experience in this indication

Study Highlights

Increased support for low-performing sites

Engaged with low-enrolling sites to ensure proper use of their local campaign budget

Creative advertising

Digital and local innovative marketing tactics to encourage patients to participate

Notalgia paresthetica cro specialty

Innovaderm managed 100% of the notalgia paresthetica studies (as per clinical trials.gov)

High compliance rate

Additional patient compensation for fully completed diary

Newsletter

Get notified to have the latest trends and be at the forefront of dermatology clinical research and innovation.

Newsletter subscription resources

*By subscribing to our newsletter, you acknowledge and agree to the terms of our privacy policy.

Blog Article

The Role of Skin barrier Dysfunction in Atopic Dermatitis—The Microbiome

Table of contents Cutaneous Dysbiosis Interplay S. aureus: Its Interaction and Impact on Skin S. aureus and Inflammation Focusing on the microbiome, Staphylococcus aureus (S. aureus) is a widespread bacterium that produces a multilayer biofilm, was shown to colonize the skin and play a critical role in Atopic Dermatitis (AD). Over 70% of people are […]

Blog Article

Enhancing Clinical Performance and Cost Efficiency: The Significance of Protocol Writing in Dermatology Trials

Did you know that protocol amendments are not only common, but also very costly? In fact, as per a recent article by Getz K. et al., 57% of protocols had at least one substantial amendment with an average of 2.3 global amendments for phase 2 and phase 3 studies. The cost to implement one protocol amendment was $141,000 US for a phase 2 study and $535,000 US for a phase 3 study. To avoid unnecessary hassle and expenses, take the time to ensure your protocols are well written and top-notch quality.

Blog Article

How to Write First-Rate Protocols for a Psoriasis Study - Focus: Study Design

The success of any clinical study is dependent upon a sturdy protocol; the overall quality of the study depends on this very document. This is especially true for multicenter studies which involve many investigators and clinical staff. This article will explore the best tips to deliver first-rate protocols in psoriasis to set you apart from the competition. Innovaderm Research Inc specializes in a spectrum of dermatological indications, namely acne vulgaris, atopic dermatitis, and psoriasis.